- Benchmark ASINB0GF7YS3N1
- MarketplaceUS
- Category ID16310091
- Analyzed Products
- Keywordglass test tube, sampling vial
- Price Range-
- Minimum Net Profit Margin10.00%
- MOQ100
- Est. Purchasing CostNo price data
- Data Date2026-07-29
- Your Budget (for new listing) (CNY)¥500,000.00
Report summary from Keble AI Agent: Listing
这个市场不适合进入：它已经进入明显的价格战区，整体只有5.88%产品可盈利，且已知利润分布里超过一半产品低于10%，这对大品牌和小商家都不是好信号。真正能跑出来的，只有少数靠强适配和差异化的新品，不是普通通用款能复制的。
Recommended Products Features Direction
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
New Brands
VS
Old Brands
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
New Brands
Old Brands
#Budget Requirement
Listing这个市场不适合现在进入，结论很明确：价格战明显，且新品牌成功率和利润结构都偏差。 你的预算 50万人民币虽然能覆盖少数单品的前期铺货、物流和投放，但面对当前市场的低利润密度和高竞争强度，够“开局”，不够“长期赢”。
数据上看，市场已经很紧：整体可识别盈利产品占比只有 5.88%，远低于健康水平；新上架产品里可盈利比例虽有 50%，但样本核心只有 Nonlbzu 这 1 个新品牌的 1 个成功品，不能代表可复制性。 反过来看，失败样本里 HUAOU 作为老品牌仍有 2 个非盈利品，分别是 B086SVVCN3（$10.99，约 14.7% 利润率，213 评）和 B0DK71B8FF（$18.27，约 7.61% 利润率，39 评），这说明连老牌也在被压利润；而核心市场的利润难度已被标记为“高”，原因就是价格竞争。唯一明显赚钱的新 ASIN 是 Nonlbzu 的 B0GF7YS3N1：售价 $15.99，约 24.78% 利润率，155 评，月销 1000，月营收约 $1.599M；但它的盈利来自基于老款做功能差异化，不是通用款硬卷，另一个新 ASIN B0GF7VXFC1 则直接失败。市场结构也显示，能卖的产品主要集中在少数样本里，总样本营收约 $19,218，说明不是广泛增长，而是少数强品在吃份额。
给大品牌的结论：只有重投放、重差异化、甚至带技术/合规壁垒，才有可能进；可对标的只有 Nonlbzu 的 B0GF7YS3N1，HUAOU 这类老品牌并不适合当小卖家模板。给小卖家的结论：不建议进，这里没有足够多的“真实小卖家成功案例”(<300评且可复制)；唯一接近的是 Nonlbzu 的 B0GF7YS3N1，但它已经是高转化、强适配、强包装的产品，不是低预算可轻松复制的路子。 如果你一定要做，至少要按 B0GF7YS3N1 的思路去做“强适配 + 无菌包装 + 差异化功能”，否则就是去打一个已经在降价的市场。
Early sourcing + logistics + marketing budget (USD)N/AExplains the budgetWith all these investments, who has profitable new releases
How many new listings are released by old brands?0.00%New listing success rate (new brands):50.00%Which new brands have these successful new listings?Alternatives- 一次性预充填针筒/预灌封系统：如果用户是为了分装或定量注射，预充填方案通常比单独采购玻璃管+塞子更省事，且减少灌装步骤。
- PP/PE塑料样品管或离心管：用于短期存放、转移和一般采样时，塑料替代品往往更便宜、更不易碎，也更容易一次性使用。
- 玻璃西林瓶（带铝盖/丁基胶塞）：如果核心需求是无菌储存和密封，西林瓶在实验室与药用场景中更普及，兼容配件更容易买到。
- 带盖玻璃样品瓶/螺口小瓶：适合非强制无菌的液体分装，使用门槛低，不需要专用推注系统。
- 微量冻存管/样品储存管：如果重点是样品保存而不是注射用途，这类管子成本通常更低，且可直接贴标、冷冻和运输。
Alternative solutions may pose a risk to your investment in certain markets.
#Brands Investment Analysis
Listing这个市场不适合进入：整体可盈利产品只有5.88%，而新品牌新上架产品只有50%看起来赚钱，但样本里同时存在明显的失败案例，说明这里不是稳定机会；更关键的是，老品牌也已经被压到14.7%和7.61%这种边缘利润，属于价格战高风险区，不是大品牌或小卖家都能安心切入的市场。
Most investment in new productsNew products with Highest revenueLeast investment in new productsNonlbzu
Recent Monthly Revenue (USD):$15,990.00(1000pcs/month)B0GF7YS3N1 (4.6/5 (155 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableOld brand with the most profitable new productsHUAOU
Recent Monthly Revenue (USD):$549.50(50pcs/month)B086SVVCN3 (4.5/5 (213 Reviews))Brand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQ
Recent Monthly Revenue (USD):$913.50(50pcs/month)B0DK71B8FF (4.5/5 (39 Reviews))Brand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQ#Differentiations
Unique productsCommon productsDifferentiation:- 11mm长塞头设计，功能更有针对性
- |
- 医用玻璃+无菌独立包装，更显专业感
- |
- 适合V1/V2 peptide pen用户，购买动机更明确
B0GF7YS3N1 (4.6/5 (155 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableSales & BSR
Differentiation:- 12×75mm试管外形更醒目，视觉辨识度高
- |
- 用途覆盖实验、收纳、装饰，图片更容易吸引点击
- |
- 黑盖透明管的对比强，货架上更显眼
B086SVVCN3 (4.5/5 (213 Reviews))Brand is an old entry in this marketOld ReleaseInsufficient Sales to Meet MOQOld ReleaseNot enough sales volume to meet 100 MOQSales & BSR
#Net Profit Margins: All vs New
Listing这个市场不值得进入。核心原因很直接：新产品利润率只到24.8%这一条还能看，但整体已是高风险价格战环境，旧品牌10个、新品牌仅1个，且新品牌新发产品成功率只有50%（样本只有2个，不能代表低风险）。 目前没有看到30~100+新品牌涌入的“超级拥挤”信号，但市场已经被老牌挤压得很厉害，且低利润/亏损产品占比很高，进入后很容易被价格和投放成本吞掉利润。
证据上，市场利润分布非常差：已知利润率里，亏损产品占35.29%，0%~10%再占17.65%，也就是52.94% 的已知产品利润率低于10%，这已经是典型价格战区；再看新产品，只能确认的2个新产品里，1个盈利、1个亏损，成功率50%，但这个结果几乎只来自 Nonlbzu，不能说明市场友好，只能说明“少数新品能活下来”。真正值得警惕的是，旧品牌 HUAOU 的两款产品都不赚钱，其中 B086SVVCN3 只有14.7% 利润率、B0DK71B8FF 只有7.61% 利润率，说明就算是老牌也在被压缩；而 Nonlbzu 的新款 B0GF7YS3N1 虽然卖到1000件/月、月营收15990美元、利润3962美元、利润率24.78%，但它的早期投入高达33856.27美元，其中广告就7614.27美元，说明要做出这种成绩，不是小商家靠低预算能复制的。此外，B0GF7YS3N1 155个评价、4.6分，暂时看不出明显刷评压力，但如果后续要靠200+评价/年去冲榜，就会更接近“predatory competitors”打法。
对两类卖家都很明确：大品牌也只是“可能进入”，不是高胜率进入；小商家更不适合。 能参考的案例只有 Nonlbzu 的 B0GF7YS3N1（新品牌、24.78%利润率、1000件/月、3.39万美元早投），但它并不证明市场容易，只证明要靠较强投放和起量能力；反面案例是 HUAOU 的 B086SVVCN3 和 B0DK71B8FF，说明老牌也在承压。结论：不要进入。
Profitability difficultyHigh Risk Due to Price CompetitionAll products distribution on different profit levels
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%otherNew products distribution on different profit levels
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%other#Top Products by Net Profit Margin
Top 20 Profitable Products
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
B0GF7YS3N1Nonlbzu2026-02-09Yes$15.991000pcs$15990.024.78%$3962.33Top 20 Profitable New Products
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
B0GF7YS3N1Nonlbzu2026-02-09Yes$15.991000pcs$15990.024.78%$3962.33#New Product Success Rates
Listing这不是一个值得进入的市场：整体成功率只有5.88%，已经低于10%的高风险线，而且最近新进入品牌只有Nonlbzu这一家，说明不是“很多新品牌都能赢”，而是少数样本里勉强跑出一个结果；真正的新品牌样本里，1个盈利、1个亏损，表面50%，但样本太小，不能当成可复制机会。 另外，已出现明显的旧品牌占位和价格压缩信号：Karter Scientific、Cadbibe、HUAOU、Labasics、Newzoll、ALWSCI、PATIKIL、ZHANXUBIO这些品牌都在同类里反复出现，说明竞争不是空白市场，而是被老玩家和通用款长期占住。
New products success rate.
What is the ratio of profitable products
Profitable (Unidentifiable released date)Profitable (Old product)Profitable (New product)Profitable (New product on old listing)New products but non profitableProfitable new products divide by brands
What is the ratio of different brands owning all profitable new products
NonlbzuNonprofitable new products divide by brands
What is the ratio of different brands owning all nonprofitable new products
Nonlbzu#Success Rate by Entry Time
Listing这个市场不值得进入，结论很明确：已进入价格战高风险区，且新品牌成功率只有50%，样本虽小但已经显示出明显分化。 2026年只看到2个新品牌相关新品：Nonlbzu 的 B0GF7YS3N1 赚钱，B0GF7VXFC1 不赚钱；而近几个月与近几年新品发布量几乎为零，说明不是机会爆发，而是只有极少数玩家在试探，市场更像是被高门槛和强竞争卡住了。
How many products released each year
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
How many products released each month
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
#Net Profit Margins by Entry Time
Different profit ratios of products released in year
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2022 0 0 0 0 0 0 0 0 2023 0 0 0 0 0 0 0 0 2024 0 0 0 0 0 0 0 0 2025 0 0 0 0 0 0 0 0 2026 0 0 0 0 1 0 0 1 ≥ 10% Profitable< 10% UnprofitableUnidentifiableDifferent profit ratios of products released in month
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2025/7 0 0 0 0 0 0 0 0 2025/8 0 0 0 0 0 0 0 0 2025/9 0 0 0 0 0 0 0 0 2025/10 0 0 0 0 0 0 0 0 2025/11 0 0 0 0 0 0 0 0 2025/12 0 0 0 0 0 0 0 0 2026/1 0 0 0 0 0 0 0 0 2026/2 0 0 0 0 1 0 0 1 2026/3 0 0 0 0 0 0 0 0 2026/4 0 0 0 0 0 0 0 0 2026/5 0 0 0 0 0 0 0 0 2026/6 0 0 0 0 0 0 0 0 ≥ 10% Profitable< 10% UnprofitableUnidentifiable#Case Study
Success Cases3ml Pen Cartridges for Peptide Pen and V1 V2 Pens, 10 Pack 3cc Empty Glass Cartridge with 11mm Long Stopper, Sterilized & Individually Wrapped
This listing is deemed profitablePrice (USD)$15.99Released TypeNew Release (2026-02-09)Brand is a new entry in this marketSize and Weight13.6 x 11.9 x 3.9 cm, 68.00gProfitable Factors
Based on old ASINDistinct functions and featuresDesign & Appearance
11mm 长塞头的 3ml 玻璃卡匣结构，针对 V1/V2 pen 注射器做了精确适配Key Buying Motive
灭菌并单独包装，兼顾无菌交付、密封性和即开即用Target Customers
需要适配 V1/V2 peptide pen 的耗材用户，强调精确兼容和无菌包装Early Investment
Investment
Monthly Revenue (Recent) (USD)$15,990.001000 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight22.48% / 24.78%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight19.27% / 21.58%Peak / Non PeakSales & BSR Performance